• Facebook
  • Youtube
  • Linkedin
  • Twitter
  • About Us
    • History
    • Leadership Team
    • Board of Directors
  • How We Work
  • Our Programs
    • Infectious Diseases
      • HIV/AIDS
      • Malaria
      • Tuberculosis
      • Hepatitis
    • Women and Children’s Health
      • Diarrhea and Pneumonia
        • Oxygen therapy
      • Maternal, Newborn, and Reproductive Health
      • Nutrition
      • Vaccines
    • Universal Health Coverage
      • Health Financing
      • Health Workforce
    • Non-Communicable Diseases
      • Cancer
      • Cervical Cancer
    • Cross-Cutting Experts
      • Market Shaping
      • Global Health Sciences
  • Where We Work
    • Africa
      • Cameroon
      • Democratic Republic of Congo
      • Ethiopia
      • Eswatini
      • Ghana
      • Kenya
      • Lesotho
      • Liberia
      • Malawi
      • Mozambique
      • Nigeria
      • Rwanda
      • Senegal
      • Sierra Leone
      • South Africa
      • Tanzania
      • Uganda
      • Zambia
      • Zimbabwe
    • Asia Pacific
      • Cambodia
      • India
      • Indonesia
      • Lao PDR
      • Myanmar
      • Papua New Guinea
      • Vietnam
    • Mesoamerica and Hispaniola
  • Resource Center
    • RFPs
    • Annual Reports
    • Financial Statements
  • Press Room
  • Blog
  • Contact
  • Join Our Team
Select Page
Policy Brief: Evaluation of Models of Differentiated Care for HIV Patients

Policy Brief: Evaluation of Models of Differentiated Care for HIV Patients

by Corina Milic | Sep 30, 2016

In Malawi, innovative models have been developed to optimize the efficiency of HIV service delivery in order to scale up access to treatment. In particular, three key models of differentiated care have emerged: multi-month prescriptions; fast-track drug refills; and...
Press Release: Aurobindo Pharma receives USFDA tentative approval for Dolutegravir

Press Release: Aurobindo Pharma receives USFDA tentative approval for Dolutegravir

by Corina Milic | Sep 22, 2016

  Aurobindo Pharma Limited is pleased to announce the tentative approval of Dolutegravir 50mg from US Food & Drug Administration (USFDA) for the treatment of HIV. This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an...
Statement from the Board of the Clinton Health Access Initiative, Inc.

Statement from the Board of the Clinton Health Access Initiative, Inc.

by Corina Milic | Sep 14, 2016

The Clinton Health Access Initiative, Inc. (“CHAI”) was founded in 2002 as a Clinton Foundation Initiative. Today, the CHAI Board of Directors, which is fully committed to and proud of CHAI’s life-saving work, announced the following changes will be implemented if...
Share this...
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on LinkedIn
Linkedin
Email this to someone
email

Related Posts

  • Linkedin
  • Twitter
  • Facebook
  • Youtube
  • About Us
    • History
    • Leadership Team
    • Board of Directors
  • How We Work
    • Our Approach
    • Guiding Principles
    • Core Competencies
  • Our Programs
    • Infectious Diseases
    • Women, Newborn, and Children’s Health
    • Universal Health
    • Non-Communicable Diseases
    • Cross-Cutting Experts
  • Where We Work
  • Resource Center
    • RFPs
    • Annual Reports
    • Financial Statements
  • Press Room
    • Blog
    • Contact
    • Join Our Team
Ⓒ 2021
  • Privacy Policy
  • Terms
  • Facebook
  • Youtube
  • Linkedin
  • Twitter

Designed by Elegant Themes | Powered by WordPress